An Update on Precision Medicine Advances In Neurodevelopmental Disorders

Area of Science:

• Neurodevelopmental Disorders
• Pharmacogenetics
• Precision Medicine

Background:

• Autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) are common neurodevelopmental disorders impacting multiple life domains.
• Current treatments for ASD and ADHD have limitations, highlighting the need for more personalized therapeutic strategies.
• The Precision Medicine Initiative aims to shift from a one-size-fits-all approach to individualized medical care.

Purpose of the Study:

• To review current research on personalized treatment approaches for ASD and ADHD.
• To provide an update on the field of pharmacogenetics and "therapy-genetics" for these conditions.
• To encourage clinical adoption of pharmacogenetic testing aligned with FDA guidelines.

Main Methods:

• Literature review of pharmacogenetic research in ASD and ADHD.
• Focus on key genes involved in drug metabolism, particularly the cytochrome P450 family (e.g., CYP2D6, CYP2C19).
• Analysis of "therapy-genetics" advancements in neurodevelopmental disorder treatment.

Main Results:

• Pharmacogenetic testing primarily targets cytochrome P450 enzymes, crucial for metabolizing many medications.
• Specific gene variants (e.g., CYP2D6, CYP2C19) influence drug efficacy and safety in individuals with ASD and ADHD.
• Emerging "therapy-genetics" approaches offer potential for highly individualized treatment plans.

Conclusions:

• Personalized medicine, driven by pharmacogenetics, holds significant promise for improving ASD and ADHD treatments.
• Clinicians should consider pharmacogenetic testing to optimize medication selection and dosage.
• Adherence to FDA recommendations for pharmacogenetic testing is crucial for advancing patient care.